 Gefitinib still represents a reasonably safe and effective treatment compared to other cancer therapies.Furthermore, epidermal growth factor receptor plays a crucial role in tumorigenesis, which is the production of a new tumor.By 2010 Two monoclonal antibodies and another small-molecule tyrosine kinase inhibitor called Erlotinib had also been developed to treat cancer.